Abstract:BACKGROUND: Thiopurine S-methyltransferase (TPMT) catalyzes the S-methylation (that is, inactivation) of mercaptopurine, azathioprine, and thioguanine and exhibits genetic polymorphism. About 10% of patients have intermediate TPMT activity because of heterozygosity, and about 1 in 300 inherit TPMT deficiency as an autosomal recessive trait. If they receive standard doses of thiopurine medications (for example, 75 mg/m2 body surface area per day), TPMT-deficient patients accumulate excessive thioguanine nucleotides in hematopoietic tissues, which leads to severe and possibly fatal myelosuppression.OBJECTIVE: To elucidate the genetic basis and develop molecular methods for the diagnosis of TPMT deficiency and heterozygosity.DESIGN: Diagnostic test evaluation.SETTING: Research hospital.PATIENTS: The TPMT phenotype was determined in 282 unrelated white persons, and TPMT genotype was determined in all persons who had intermediate TPMT activity (heterozygotes) and a randomly selected, equal number of persons who had high activity. In addition, genotype was determined in 6 TPMT-deficient patients.MEASUREMENTS: Polymerase chain reaction (PCR) assays were developed to detect the G238C transversion in TPMT*2 and the G460A and A719G transitions in TPMT*3 alleles. Radiochemical assay was used to measure TPMT activity. Mutations of TPMT were identified in genomic DNA, and the concordance of TPMT genotype and phenotype was determined.RESULTS: 21 patients who had a heterozygous phenotype were identified (7.4% of sample [95% CI, 4.7% to 11.2%]). TPMT*3A was the most prevalent mutant allele (18 of 21 mutant alleles in heterozygotes; 85%); TPMT*2 and TPMT*3C were more rare (about 5% each). All 6 patients who had TPMT deficiency had two mutant alleles, 20 of 21 patients (95% [CI, 76% to 99.9%]) who had intermediate TPMT activity had one mutant allele, and 21 of 21 patients (100% [CI, 83% to 100%]) who had high activity had no known TPMT mutation. Detection of TPMT mutations in genomic DNA by PCR coincided perfectly with genotypes detected by complementary DNA sequencing.CONCLUSIONS: The major inactivating mutations at the human TPMT locus have been identified and can be reliably detected by PCR-based methods, which show an excellent concordance between genotype and phenotype. The detection of TPMT mutations provides a molecular diagnostic method for prospectively identifying TPMT-deficient and heterozygous patients.

Thiopurine Methyltransferase Genetic Polymorphism Analysis of Azathioprine Induced Myelosuppression in SLE

Thiopurine methyltransferase gene polymorphisms and activity in Chinese patients with inflammatory bowel disease treated with azathioprine.

Thiopurine Methyltransferase Gene Polymorphisms in Chinese Patients with Inflammatory Bowel Disease

[The Study on Hereditary Polymorphism of Thiopurine S-methyltransferasein Chinese Han Population of Shanghai Area].

Significance of genetic polymorphism of the thiopurine S-methyltransferase for individualizing 6-mercaptopurine chemotherapy

Advances in genetic polymorphism of NUDT15 and leucopenia caused by thiopurines

Molecular Diagnosis of Thiopurine S-Methyltransferase Deficiency: Genetic Basis for Azathioprine and Mercaptopurine Intolerance

[Relationship Between Single Nucleotide Polymorphisms in Thiopurine Methyltransferase Gene and Tolerance to Thiopurines in Acute Leukemia].

Correlation between Thiopurine S-methyltransferase and Thiopurines Toxicity in Patients with Inflammatory Bowel Disease

Role of TPMT Genetic Polymorphism in the Individualized Treatment of Thiopurine Drug

Association Between Genetic Polymorphisms of Metabolic Enzymes and Azathioprine-Induced Myelosuppression in 1,419 Chinese Patients: A Retrospective Study

[The Effect of the Adverse Events with Thiopurine S-methyltransferase Gene Mutation on Outcome of Childhood Acute Lymphoblastic Leukemia].

Study on the Relationship Between Genetic Polymorphism of TPMT and ITPA with Adverse Drug Reactions in 6-Mercaptopurine Treatment

Association Between Thiopurine S-Methyltransferase Polymorphisms And Azathioprine-Induced Adverse Drug Reactions In Patients With Autoimmune Diseases: A Meta-Analysis

[Association Between Metabolic Enzyme Genotype of Azathioprine and Drug Tolerance in Patients with Rheumatic Diseases].

Correlation Between TPMT Polymorphisms and Azathioprine Toxicity in the Treatment of Inflammatory Bowel Disease: A Meta Analysis

Evaluation of thiopurine methyltransferase genotyping and enzyme activity detection in treatment of patients with inflammatory bowel disease

Prospective Evaluation of Pharmacogenomics and Metabolite Measurements Upon Azathioprine Therapy in Inflammatory Bowel Disease

Should Thiopurine Methyltransferase Genotypes and Phenotypes Be Measured Before Thiopurine Therapy in Patients with Inflammatory Bowel Disease?

Thiopurine S-methyltransferase Polymorphisms and Thiopurine Toxicity in Treatment of Inflammatory Bowel Disease.

Determination of intra-ethnic differences in the polymorphisms of thiopurine S-methyltransferase in Chinese.